Zalicus Initiates the First of Two Phase 2a Studies with Z160, a First-in-Class, Oral, State-Dependent, Selective N-type Calcium Channel Blocker, for the Treatment of Chronic Neuropathic Pain (NASDAQ: ...

An exclusive out-licensing deal could be worth up to $475 million to Neuromed Pharmaceuticals Ltd., which entered an agreement with Merck & Co. Inc. on N-type calcium channel blockers for pain and ...

Please provide your email address to receive an email when new articles are posted on . An ongoing study showed improvements in SSc severity, disease-related pain, Raynaud’s symptoms and ...

NJIT Associate Professor Victor Matveev, PhD, in the department of mathematical sciences, was part of a research team that published "N-type Ca2+ channels carry the largest current: Implications for ...